BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Howard M, Barber J, Alizai N, Rostami-Hodjegan A. Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics. Expert Opin Drug Metab Toxicol 2018;14:1315-30. [PMID: 30465453 DOI: 10.1080/17425255.2018.1546288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Doki K, Kuga K, Aonuma K, Ieda M, Homma M. Utilizing physiologically based pharmacokinetic modeling to predict theoretically conceivable extreme elevation of serum flecainide concentration in an anuric hemodialysis patient with cirrhosis. Eur J Clin Pharmacol 2020;76:821-31. [DOI: 10.1007/s00228-020-02861-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Alsultan A, Alghamdi WA, Alghamdi J, Alharbi AF, Aljutayli A, Albassam A, Almazroo O, Alqahtani S. Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia. Saudi Pharm J 2020;28:1217-27. [PMID: 33132716 DOI: 10.1016/j.jsps.2020.08.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 El-khateeb E, Vasilogianni A, Alrubia S, Al-majdoub ZM, Couto N, Howard M, Barber J, Rostami-hodjegan A, Achour B. Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice. Pharmacology & Therapeutics 2019;203:107397. [DOI: 10.1016/j.pharmthera.2019.107397] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
4 Cailleaux S, Sanchez-Ballester NM, Gueche YA, Bataille B, Soulairol I. Fused Deposition Modeling (FDM), the new asset for the production of tailored medicines. J Control Release 2021;330:821-41. [PMID: 33130069 DOI: 10.1016/j.jconrel.2020.10.056] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
5 Durán-Lobato M, Niu Z, Alonso MJ. Oral Delivery of Biologics for Precision Medicine. Adv Mater 2020;32:e1901935. [PMID: 31222910 DOI: 10.1002/adma.201901935] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
6 Tang F, Ng CM, Bada HS, Leggas M. Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments. Clin Transl Sci 2021;14:1231-49. [PMID: 33650314 DOI: 10.1111/cts.12994] [Reference Citation Analysis]
7 Doki K, Neuhoff S, Rostami-Hodjegan A, Homma M. Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling. CPT Pharmacometrics Syst Pharmacol 2019;8:118-26. [PMID: 30659778 DOI: 10.1002/psp4.12382] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]